The transplantation of encapsulated dopamine-secreting cells into the striatum represents one potential means of treating Parkinson's disease. The present study investigated the ability of encapsulated PC12 cells, which are derived from rat pheochromocytoma, to supply L-dopa and dopamine into the primate brain in the long term and to effect functional improvement in the animals. Following polymer encapsulation, PC 12 cells were transplanted into the striatum of hemiparkinsonian monkeys. The secretion of L-dopa and dopamine from the encapsulated cells, the morphology of these cells, the histology of the host striatum surrounding the capsule, and functional changes in the host animals were examined 1, 6, and 12 months after transplanta tion. Analysis of retrieved capsules revealed that the PC 12 cells survived and continued to release L-dopa and dopamine even 12 months after transplantation. The histological response of the host brain surrounding the capsules was minimal and there were no signs of immunological rejection or tumor formation. The physical condition of the host animals was good for 12 months, and hematologic and cerebrospinal fluid analysis revealed that no animals suffered from infection or immunological reaction. These PC12 cell-grafted monkeys showed improvements in hand movements after transplantation, effects that lasted for at least 12 months. These results further support the potential use of this approach for the treatment of Parkinson's disease.
INTRODUCTION
Parkinson's disease is characterized by dopamine depletion within the striatum associated with the pro gressive loss of dopaminergic neurons in the substantia nigra (10, 11) . A basic principle of neural transplantation for Parkinson's disease is to provide a stable supply of L-dopa or dopamine directly into the striatum. PC 12 cells, which are derived from rat pheochromocytoma, are known to produce large amounts of L-dopa and do pamine and are theoretically an unlimited donor source for neural transplantation (1, 9, 14) . In a previous study, we showed that implantation of PCI2 cells alone (with out encapsulation) into the primate striatum resulted in immunological rejection because these cells are xenoge neic cells (15) . We have also shown that polymer encap sulation of cells permitted the transplantation of multiple cell types into the brain for delivery of neurotransmitters as well as neurotrophic factors because encapsulated cells were immunologically isolated and tumor forma tion could be prevented due to the rigid nature of the capsule (3, 5, 6, 13) . In the present study, we investigated the long-term effect of encapsulated dopamine-secreting cells implanted into the striatum of parkinsonian model monkeys.
MATERIALS AND METHODS
Nineteen monkeys were employed in the study ac cording to approved guidelines of the institutional ani mal case and use committee of Okayama University. Animals were housed one per cage on a 12-h on and 12-h off lighting schedule during the study. Left intracarotid infusions of l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (0.4 mg/kg) were performed on all of the host animals to create hemiparkinsonian model monkeys (9) . PC 12 cells were maintained in vitro and harvested prior to encapsulation, and hollow fibers of polysulfone or poly(acrylonitrile vinylchloride) copolymer were pre pared as previously described (3, 5) . PC 12 cells were prepared as a single cell suspension and infused into in dividual capsules 7-12 mm in length at a density of 1 x 10 7 cells/ml. After this infusion process, the access port was sealed with light-cured plastic. The PC 12 cellloaded devices were assayed to quantify basal and potas sium-stimulated L-dopa and dopamine release. These devices were tethered by placing a silicone tube over the sealed loading port.
Three months following the MPTP infusion, the in fused monkeys were placed in a stereotaxic apparatus and encapsulated PC 12 cells with a silicone tether were grafted into the left striatum. The host animals did not receive any immunosuppressive agents. The fine motor coordination of the upper limbs was examined in each monkey using a food pick-up task. Raisins were placed within a 3 x 3 matrix of recessed food wells. Nine rai sins were placed on the board for each trial, and the time it took for the monkeys to retrieve all nine raisins was noted. Host animals were euthanized under deep anes thesia 1, 6, and 12 months after transplantation. Follow ing capsule retrieval from the host striatum, capsules were placed in phosphate HBSS for 30 min. The phos phate HBSS was removed and HEPES HBSS was poured onto the capsules for an additional 15 min of each of basal and potassium-stimulated catecholamine analysis. Each sample was assayed using high-perfor mance liquid chromatography with electrochemical de tection to detect L-dopa and dopamine. After chemical analysis, the capsules were fixed in 4% paraformalde hyde and 0.5% glutaraldehyde solution, rinsed in PBS, and dehydrated. Glycol methacrylate was next added to the capsules, which were then rinsed with the embed ding solution, transferred to flat molds, and embedded in glycol methacrylate. Sections 5 pm thick were moun ted on glass slides and stained with hematoxylin and eosin.
For histological analysis of the host brain, it was postfixed in 4% paraformaldehyde and sectioned using a freezing microtome. Sections were subjected to immu nocytochemical analysis using antibodies to glial fibril lary acidic protein (GFAP).
During the experimental period, the blood cell count of the host animals as well as measurement of the CD4/ CD8 ratio were performed periodically. Cerebrospinal fluid (CSF) was collected from some of the host animals to evaluate the cell counts and protein levels.
RESULTS
The cell-loaded devices were easily retrieved with lit tle host tissue adhering to the capsule wall. At 1, 6, and 12 months following transplantation, all capsules were removed intact, no evidence having been found that any capsule had broken either in situ or during the retrieval procedure, and morphological analysis showed that all The long-term viability of the PC 12 cells was paral leled by continuous, stable secretion of L-dopa and do pamine (Fig. 1) . The levels of L-dopa produced by the capsules were 7.32 ± 1.54 ng/capsule prior to implanta tion and 6.53 ± 1.37, 5.77 ±1.54, and 5.88 ±1.05 ng/ capsule at 1, 6, and 12 months after transplantation, re spectively. The levels of dopamine produced by the cap sules were 1.28 ±0.23 ng/capsule prior to implantation and 1.05 ±0.11, 0.87 ± 0.25, and 0.83 ± 0.09 ng/capsule at 1, 6, and 12 months after transplantation, respectively. The level of L-dopa and dopamine secreted from the encapsulated PC 12 cells increased two-to threefold un der conditions of potassium stimulation.
Hematoxylin and eosin-and GFAP-immunostained sections revealed that all capsules were correctly placed within the striatum. Very few macrophages were ob served around the capsules and a relatively normal cytoarchitectonic pattern of striatal neurons was seen. GFAP staining demonstrated that the host response to the capsules was minimal around the grafted site. There was no tumor formation by the grafted PC 12 cells within the host brain and no apparent immunological reaction around the capsule.
The results of pick-up task are shown in Figure 2 . Although the host animals that received capsules con taining no cells showed no functional recovery, those that received PC 12 capsules demonstrated functional re covery of the right upper limbs after transplantation. As the figure shows, the fine motor coordination of the right upper limbs was still slightly disturbed compared with that of the left upper limbs, which were not affected by MPTP toxicity. The functional effect of PC 12 cell graft ing continued up to 12 months after transplantation.
All of the host animals were physically healthy after transplantation until the time of sacrifice. Neither the blood cell count nor the CD4/CD8 ratio changed signifi cantly after transplantation, suggesting that there was no general infection or immunological reaction due to the implantation of PC 12 cell loaded capsules. CSF samples after transplantation also showed no significant increase of the leukocyte count or the protein level, and were sterile.
DISCUSSION
The present study demonstrates that transplantation of encapsulated PC 12 cells induced long-term functional recovery in a primate model of Parkinson's disease without immunosuppression. Surviving PC 12 cells that continued to secrete L-dopa and dopamine were found in all animals at 1, 6, and 12 months after transplanta tion. Host response to these capsules was minimal throughout the experiments.
Parkinson's disease is a chronic, progressive neuro degenerative disorder characterized by a profound loss of dopaminergic neurons in the substantia nigra pars compacta with a concomitant loss of dopamine within the striatum (10, 11) . Neural transplantation is a promis ing approach to the treatment of Parkinson's disease, and fetal nigral cell or paraneurons such as chromaffin cells and sympathetic ganglion cells have been used as donor tissues (2, 4, 7) . Dopamine-producing cell lines such as PC 12 cells are a good possible donor source because an unlimited number of donor cells can be pro vided. However, when these cells were grafted into the xenogeneic brain without immunosuppression, they could not survive because of immunological rejection by the host (15) . The selective nature of a polymeric membrane prevents contact between the implanted cells and elements of the recipient's immune system, allow ing transplantation of even xenogeneic tissue without immunosuppression. The use of an encapsulating mem brane eliminates the risks associated with immunosup pressive drug therapy, and could provide additional sources of cells/tissue for transplantation (8) . This tech nique also allows for easy retrieval of the transplanted cells, should that be necessary for safety or replacement reasons. The reduction in risk of tumor formation and viral transmission in encapsulated transplants provides additional safety margins. With the use of encapsulated cell grafting techniques, many reports have stated that PC 12 cells and genetically modified trophic factor-se creting cells can be transplanted into parkinsonian model animals with favorable results (1, 9, 12, 14) . Adding fur ther data to these previous reports, the present study demonstrated the long-term efficacy and safety of this procedure in the primate brain.
Stereotaxic thalamotomy or pallidotomy has been used as a surgical treatment for Parkinson's disease (10, 11) . In our department, we have so far performed more than 500 stereotaxic procedures for patients with Parkinson's disease with favorable results, but most of these patients, especially those who received pallidoto mies, needed to continue oral administration of L-dopa after surgery. We consider that a combination of stereo taxic surgery and intrastriatal encapsulated dopamine-se creting cell grafting will soon be usable for patients with Parkinson's disease. More concretely, for patients whose main symptoms are tremor and rigidity, stereotaxic thal amotomy will, we believe, be performed in combination Figure 2 . Results of pick-up task of the grafted animals. Although the host animals receiving capsules without cells did not show any functional recovery, those receiving PC 12 capsules demon strated functional recovery in the right upper limbs after transplantation, sec: time in seconds taken for animals to retrieve 9 raisins, mo: month(s).
with intrastriatal grafting of encapsulated dopamine-se creting cells, and for those whose main symptom is aki nesia, stereotaxic pallidotomy should come into use in combination with intrastriatal grafting of encapsulated dopamine-secreting cells. We conclude that encapsu lated dopamine-secreting cell grafting is a promising ap proach for the treatment of Parkinson's disease because of its long-term efficacy and safety in the primate brain.
